On the basis of generation of an infectious cDNA clone for the BHM26 strain of bovine enterovirus cluster B (BEV-B), 22 sites on different loops of the BHM26 capsid were selected according to an alignment of its sequence with the structural motifs of BEV-A strain VG-5-27 for insertion of the foot-and-mouth disease virus (FMDV) type O-conserved neutralizing epitope 8E8. Two recombinant viruses, rBEV-A1 and rBEV-DE, in which the FMDV epitope was inserted into the VP1 B-C or D-E loops, were rescued by transfection of BHK-21 cells with the in vitrotranscribed RNA of the recombinant BHM26 genome-length cDNA constructs. The two epitopeinserted viruses were genetically stable and exhibited growth properties similar to those of their parental virus in BHK-21 and IBRS-2 cells, which are susceptible to both BEV and FMDV. However, the two recombinant BEVs (rBEVs) had a significantly lower growth titre than those of the parental virus BHM26 in MDBK and Marc145 cells, which are susceptible to BEV but not to FMDV. These results indicated that insertion of the FMDV epitope into the VP1 B-C or D-E loops of the BEV particle altered the replication properties of BEV. In addition, the two rBEVs were sensitive to neutralization by the FMDV type O-specific mAb 8E8, and anti-FMDV IgG antibodies were induced in mice by intramuscular inoculation with the rBEV-A1 and rBEV-DE viruses. Our results demonstrate that the VP1 B-C and D-E loops of the BEV-B particle can effectively display a foreign epitope, making this an attractive approach for the design of BEV-vectored and epitope-based vaccines.
INTRODUCTION
Bovine enterovirus (BEV), which is a member of the family Picornaviridae, genus Enterovirus, forms two phylogenetic clusters, BEV-A and BEV-B, which comprise two and three genotypes, respectively (Zell et al., 2006) . The virus particle is composed of one molecule of positive-stranded RNA encapsulated within 60 copies of each of the structural proteins, VP1, VP2, VP3 and VP4 (Hoey & Martin, 1974) . Electron micrographs have revealed that hydrated native BEV particles are 27-30 nm in diameter and that the virion is a smooth sphere. BEV was first isolated in the late 1950s (Huck & Cartwright, 1964; Knowles & Barnett, 1985) , from (i) faeces of cattle with symptoms of pneumonia, respiratory disease, enteritis, dysentery and fertility disorders; (ii) fetal fluids from an aborted calf; (iii) the faeces of apparently healthy animals; and (iv) sewage, treated effluents and materials from a farm environment.
Difficulties in reproducing clinical symptoms following the experimental infection of animals led to the conclusion that BEV is of only minor veterinary medical importance. However, BEV has been shown to be widely detectable in farm environments and has thus been proposed as a marker of faecal contamination from cattle (Ley et al., 2002) . More importantly, it is generally assumed that BEV is avirulent and thus would be a useful vector for the delivery of small molecules to the gut. Several characteristics of BEV also make it a good candidate for the development of a vaccine vector for expressing foreign epitopes. First, the BEV particle is physically very stable; for example, it is resistant to lipid solvents (e.g. chloroform) and is stable at pH 2-10. Secondly, as mentioned above, BEV is currently considered avirulent in cattle, making it safe to use as a vaccine vector. Thirdly, because BEV enters its host via the enteric tract, it could be administered orally as a vaccine vector to stimulate mucosal immunity.
In 1989, an engineered poliovirus chimaera expressing an epitope of human immunodeficiency virus type 1 (HIV-1) gp41 was reported to elicit broadly reactive anti-HIV-1 neutralizing antibodies (Evans et al., 1989) , suggesting that a picornavirus might be permissive for epitope insertion. The incorporation of peptides into the capsid proteins of other picornaviruses, including human rhinoviruses (Arnold et al., 2009 ) and foot-and-mouth disease virus (FMDV) , has subsequently been employed as a method for eliciting epitope-specific antibodies. In addition, Seago et al. (2012) used reverse genetics to introduce haemagglutinin (HA) and FLAG tags into the FMDV capsid; the resulting HA-and FLAG-tagged FMDVs offer a feasible alternative to the current methods of vaccine concentration and purification. These results demonstrated that the capsid proteins of picornaviruses are permissive for foreign peptide insertion. Resolution of the three-dimensional structure of the BEV-A particle (Smyth et al., 1995) has provided detailed information on the location, orientation and structure of the viral proteins in the virus particle, making it possible to construct recombinant BEVs (rBEVs) by selecting epitope insertion sites in their capsid proteins. In a recent study, a BEVbased vector expressing an FMDV antigenic region was constructed (Chu et al., 2013) by insertion of the VP1 G-H loop (aa 141-160) of FMDV into the VP1/2A junction of BEV. However, rBEVs that display foreign epitopes on the capsid proteins of the BEV particle have not been constructed.
To explore the potential of BEV-B to display a known foreign epitope with the aim of developing an efficient viral vector platform, we constructed an infectious cDNA clone of the BEV-B BHM26 strain and used this strain to engineer recombinant BEVs to display the type Oconserved neutralizing epitope of FMDV on the viral capsid. Two rBEVs with FMDV epitope insertions on the VP1 B-C or D-E loops were rescued, and their growth titres did not significantly decrease in cells susceptible to both BEV and FMDV. Furthermore, the two rBEVs were neutralized in vitro by the anti-FMDV type O-specific mAb 8E8 and could induce anti-FMDV IgG antibodies in mice. These results provide experimental support for the further development of BEV-vectored, epitope-based vaccines.
RESULTS

Construction of a BEV BHM26 infectious cDNA clone
Three cDNA fragments, A, B and C, were amplified from the genome of the BEV-B BHM26 strain, and each was cloned sequentially into the pOK12 vector to construct a full-length cDNA clone downstream of the T7 promoter, designated pOKT7-BHM26 ( Fig. 1a ). pOKT7-BHM26 was linearized by BglII digestion and used as a template for in vitro transcription with T7 RNA polymerase. The resultant transcripts were purified and used to transfect BHK-21 cells. The cytopathic effect (CPE) of the RNA-transfected cells was observed as an indicator of productive virus infection (Fig. 1b, c) . As shown in Fig. 1(b) , the RNA-transfected cells displayed a typical CPE (including cell rounding, aggregation and floatation) similar to cells infected by the WT virus (Li et al., 2012) , and immunofluorescence assay (IFA) detection revealed that the rescued BEV reacted with anti-BEV-B serum ( Fig. 1d, e ). Restriction enzyme analysis of the PCR product revealed that digestion of the PCR product with PvuII yielded two fragments of 740 and 260 bp in the case of the parental virus BHM26, whilst PvuII digestion of the rescued virus yielded a single intact band of 1000 bp (data not shown) due to the artificial elimination of the PvuII restriction enzyme site in the VP1 region of the rescued virus. The one-step growth curve of the rescued virus was similar to that of its parental virus BHM26, and the peak titres of virus growth (approx. 10 7.5 TCID 50 per 0.1 ml) were very similar. Sequence analysis revealed that the genome sequence of the rescued virus did not change after 10 passages, indicating that the virus was genetically stable. Overall, these results demonstrated that the RNA transcribed from the BHM26 cDNA clone was capable of generating infectious BEV.
Generation of recombinant BEVs displaying the 8E8 epitope
Based on the three-dimensional structure of the BEV-A particle (Smyth et al., 1995) and comparison of the sequences of the capsid proteins between BEV-A and BEV-B, the detailed residue numbering corresponding to the viral capsid loops of BEV-B BHM26 was determined. A total of 22 potential insertion sites within the different loops of the VP1, VP2 and VP3 capsid proteins of BHM26 were selected for insertion of the FMDV 8E8 epitope (ARGDLQVLTPKA). Thus, 22 recombinant plasmids, as described in Methods, were constructed by inserting a sequence encoding ARGDLQVLTPKA at different positions in the BHM26 capsid as described in Table S2 (available in JGV Online). Sequence analysis demonstrated that the 8E8 epitope-encoded sequence was correctly inserted at the desired position in all of the recombinant plasmids. The recombinant plasmids were linearized by BglII digestion as templates for in vitro RNA synthesis. After transfection of the in vitro-transcribed RNA into BHK-21 cells, two recombinant BEVs designated rBEV-A1 and rBEV-DE, in which the 8E8 epitope was inserted into the BEV VP1 B-C and D-E loops, respectively, were obtained. BHK-21 cells infected with the recombinant BEVs exhibited typical CPEs, as did the cells infected with the rescued parental BEV (Fig. 1b ). Furthermore, IFA detection ( Fig. 2) and Western blot analysis (Fig. 3 ) demonstrated that the rBEV-A1 and rBEV-DE viruses reacted with both anti-BEV-B serum and the anti-type O FMDV mAb 8E8. In addition, rBEV-A1 and rBEV-DE were neutralized by the mAb 8E8 at high titres of 1 : 2048 and 1 : 1024, respectively. These results demonstrated that the BEV-B particle can display the exogenous epitope on the B-C and D-E loops of VP1, suggesting that these loops on VP1 are the most flexible region of BEV-B for the easy insertion of foreign epitope peptides.
The insertion of a 12 aa peptide epitope into the VP1 region of rBEV-A1 and rBEV-DE caused the VP1 protein to migrate more slowly than the VP1 from the parental virus BHM26, and the reactivity of the rBEVs to the anti-BEV-B serum was much weaker than that of BHM26, as assessed by Western blot analysis (Fig. 3a) . These results indicated that the insertion of a foreign epitope into the B-C loop or D-E loop of VP1 might influence the antigenicity of BHM26. Sequence analysis revealed that the 8E8 epitope-encoded sequence in the rBEVs did not change after 10 passages, suggesting that the B-C and D-E loops of BEV-B VP1 can stably express the 8E8 epitope. The rBEV-A1 and rBEV-DE viruses were generated from the recombinant plasmids pBEV-A1 and pBEV-DE, respectively. By contrast, no viable virus was generated from cells transfected with the 20 other recombinant plasmids listed in Table S2 . Thus, the VP1 B-C and D-E loops of the BHM26 viral particle are permissive for epitope insertion, whereas the other 20 sites within the different loops of the VP1, VP2 and VP3 capsid proteins do not permit insertion of the foreign epitope. These results indicated that the tolerated insertion sites on the capsid of the BEV-B particle are limited.
Effects of FMDV epitope insertion on rBEV replication
To investigate the possible effects of the insertion of the 8E8 epitope into the VP1 B-C or D-E loops on BEV growth, several cell lines (BHK-21, IBRS-2, MDBK and Marc145 cells) were infected with either rBEVs or their parental virus BHM26 at an m.o.i. of 5, and the infectious titres in the supernatants of the infected cells were measured. This experiment was repeated independently three times, and statistical analysis was performed using a A T7 Display of an FMDV epitope by BEV-B VP1 loops two-tailed paired Student's t-test (n53) in which values of P,0.05 were considered statistically significant. The growth curves of the rBEVs and their parental virus were similar (data not shown); however, the peak titres of the rBEVs were different (Fig. 4) . The rBEV-A1 and rBEV-DE viruses exhibited slightly lower titres than the parental virus BHM26 in BHK-21 and IBRS-2 cells, which are susceptible to both BEV and FMDV, but these differences were not significant (P.0.1) ( Fig. 4 ). By contrast, in MDBK and Marc145 cells, which are susceptible to BEV but not to FMDV, the titres of the rBEV-A1 and rBEV-DE viruses were significantly lower than those of the parental virus BHM26 (P,0.05 for rBEV-DE in Marc145 cells; P,0.01 for rBEV-A1 and rBEV-DE in MDBK cells, and for rBEV-A1 in Marc145 cells) ( Fig. 4) . The rBEV-A1 and rBEV-DE viruses were generated by inserting the 8E8 epitope into the B-C loop at position 82/83 of VP1 and into the D-E loop at position 124/125 of VP1, respectively. We presume that the insertion of the foreign peptide into positions 82/83 and 124/125 of VP1 negatively influenced BEV replication in BHK21, IBRS-2, MDBK and Marc145 cells, which are susceptible to BEV, whilst the RGD motif of the 8E8 epitope (ARGDLQVLTPKA), which is located in the VP1 G-H loop, is involved in receptor binding to FMDV (Berinstein et al., 1995; Duque & Baxt, 2003; Fox et al., 1989; Jackson et al., 2000 Jackson et al., , 2002 Jackson et al., , 2004 Mason et al., 1994; Neff & Baxt, 2001; Neff et al., 2000) . Thus, the receptorbinding function of the 8E8 epitope might compensate for the negative influence of the epitope insertion in BHK-21 and IBRS-2 cells, which are susceptible to both FMDV and BEV; however, the 8E8 epitope has no compensatory effect in MDBK and Marc145 cells, which are susceptible to BEV but not to FMDV. These results suggest that the epitope insertions at positions 82/83 and 124/125 of the VP1 capsid protein may have changed the replication properties of BEV by changing the receptor-binding motif of the VP1 B-C loop or D-E loop and that positions 82/83 and 124/ 125 of the VP1 capsid protein might be the receptorbinding regions of BEV-B.
Serum antibody response induced by rBEVs in mice
To evaluate the immunogenicity of the 8E8 epitope displayed on rBEV-A1 and rBEV-DE, 6-week-old specific-pathogen-free BALB/c mice were inoculated intramuscularly with the rBEVs or their parental virus, and sera were collected at 2-week intervals to detect the humoral immune response to type O FMDV and BEV-B by indirect ELISA. The kinetics of BEV-and FMDV-specific IgG antibodies in the inoculated mice are depicted in Fig. 5 .
The results showed that the seroconversion of IgG antibodies to BEV and FMDV occurred at week 2 postinoculation (p.i.) in the mice inoculated with the rBEVs; after the booster at week 2 p.i., the level of IgG antibodies to BEV and FMDV in the inoculated mice increased dramatically and reached a maximum at week 10, followed by a slow decline until week 14 ( Fig. 5 ). As expected, the control BHM26-inoculated mice had no IgG antibodies against FMDV (Fig. 5b ). In addition, the anti-BEV-B antibody titres in the mice inoculated with the rBEVs were similar to those in the mice inoculated with the parental virus BHM26 (Fig. 5a ). These results indicated that the 8E8 epitope displayed on the rBEVs retained its immunogenicity and that the introduction of the 8E8 epitope did not influence the immunogenicity of BHM26. Next, serum samples at the peak day (week 8 p.i.) in all of the mice were serially diluted twofold starting at a dilution of 1 : 8, and the titres of BEV-and FMDV-specific neutralizing antibodies were detected by a virus neutralization assay (the virus neutralization assay was independently repeated three times). The titres of FMDV-specific neutralizing antibodies in the mice inoculated with the rBEVs were less than 1/16 (Table S3 ). According to the standard of the Office International des Epizooties (OIE), a titre of less than 1/16 is considered negative, and thus these data indicated that FMDV-specific neutralizing antibodies were not induced in mice by intramuscular inoculation of the rBEVs. Surprisingly, neither the rBEVs nor the parental virus BHM26 induced anti-BEV neutralizing antibodies (Table S3 ). The mechanism of this strange phenomenon is unclear; however, BEV is an enteric pathogen and might induce neutralizing antibodies in the mucosal lining of the gastrointestinal tract. Therefore, the immunogenicity of the rBEVs should be evaluated by oral inoculation of susceptible animals, such as neonatal calves.
DISCUSSION
Viral vectors are commonly used by scientists as tools to deliver genetic material into cells. A wide range of virus families is currently under intensive development as vaccine vectors for either human or veterinary use Draper & Heeney, 2010) . Several characteristics of BEV, including its stable physico-chemical properties, avirulence in cattle and ability to stimulate mucosal immunity, make it a good candidate for the development of a vaccine vector. Thus, in the present study, we first constructed an infectious cDNA clone for the BHM26 strain of BEV-B. Subsequently, based on an alignment with the structural motifs of BEV-A strain VG-5-27, 22 sites on the capsid loops of the BHM26 particle were selected for insertion of the FMDV type O-conserved neutralizing epitope to explore the potential of BEV-B as a vaccine vector for expressing small peptides. We found that position 82/83 on the B-C loop of VP1 and position 124/125 on the D-E loop of VP1 were permissive for insertion of an epitope in the BHM26 particle, whilst 20 other sites within BHM26 (as described in Table S2 ), including different loops on the VP1, VP2 and VP3 capsid proteins, could not tolerate insertion of the foreign epitope. These results suggested that the tolerated insertion sites in the capsid of the BEV-B particle are limited. The two recombinant BEVs in which the FMDV epitope was inserted into the B-C or D-E loops of VP1 were genetically stable. These rBEVs could react with the anti-type O FMDV mAb 8E8 in vitro and could induce serum IgG antibodies to FMDV in vivo. These results demonstrated that the FMDV 8E8 epitope was effectively displayed on the B-C and D-E loops of BEV-B VP1. Thus, the BEV-B vector platform established in this study can be used for the further development of BEVvectored, epitope-based vaccines. This study represents the first exploration of the potential of BEV-B to display foreign epitopes on the viral capsid.
Our results do not provide direct evidence that the FMDV 8E8 epitope is displayed on the surface of the BEV-B particles. However, based on an alignment with the structural motifs of BEV-A VG-5-27 (Smyth et al., 1995) , positions 82/83 and 124/125 of the VP1 capsid protein of BHM26 particle have surface-exposed characteristics. In addition, IFA detection (Fig. 2) , Western blot analysis ( Fig. 3) and virus neutralization assays demonstrated that the rBEV-A1 and rBEV-DE viruses could react with the anti-type O FMDV mAb 8E8 in vitro. Taken together, these results suggested that the FMDV 8E8 epitope was displayed on the surface of BEV-B particle. In addition to the correct display of the epitope on the surface of the capsid proteins, another critical element for the effective display of the epitope is tolerance of the BEV capsid proteins to the insertion of a foreign peptide sequence. Thus, it is essential to know the maximum size limit of the inserted sequence that BEV capsid proteins can stably accept without disrupting the virion or decreasing gene expression.
Receptor binding is one of the most important determinants of viral tropism. However, studies of the receptor binding of BEV are scarce. Compared with other picornaviruses, the capsid proteins VP1 and VP3 of BEV-A and BEV-B deviate considerably in six regions (R1: aa 86-92, R2: aa 127-138, R3: aa 198-208, R4: aa 226-230, R5: aa 266-273 and R6: aa 180-187; residue numbering corresponds to the BEV-A structure from the Protein Data Bank) (Goens et al., 2004) . These six regions lie at or within the so-called canyon, which is believed to be involved in capsid protein-host receptor binding (Rossmann, 2002; Smyth & Martin, 2001) . In this study, insertion at position 82/83 or 124/125 of the VP1 capsid protein influenced the replication properties of BEV-B BHM26. In addition, positions 82/83 and 124/125 of the VP1 capsid protein are homologous to the previously published R1 and R2 regions of BEV-A, respectively (Goens et al., 2004; Rossmann, 2002; Smyth & Martin, 2001) . These results suggest that the domains adjacent to positions 82/83 and 124/125 of the VP1 capsid protein are probably the receptor-binding regions of BEV-B BHM26.
The efficacy of most viral vaccines is a result of their ability to elicit neutralizing antibodies (Plotkin, 2001) , and the development of immunogens that elicit neutralizing antibodies remains a high priority for the development of effective vaccines. Foreign epitope insertion into the variable regions of HIV and simian immunodeficiency virus Env proteins has been examined for its potential to drive viral neutralization (Laird & Desrosiers, 2007; Pantophlet et al., 2009; Ren et al., 2005; Rong et al., 2007) . The incorporation of peptides into the capsid proteins of non-enveloped viruses, including human papillomavirus, poliovirus, human rhinovirus, FMDV and porcine parvovirus, has been employed as a method for eliciting epitope-specific antibodies (Evans et al., 1989; Kitson et al., 1991; Mattion et al., 1994 Mattion et al., , 1995 Sedlik et al., 1997; Thomas et al., 2003; Varsani et al., 2003; Wang et al., 2012) . In the current study, anti-BEV or anti-FMDV IgG antibodies were induced in mice by intramuscular inoculation with the rBEV-A1 and rBEV-DE viruses (Fig.  5 ). However, no neutralizing antibodies against type O FMDV were detected in the mice inoculated with the rBEVs (Table S3) . Similarly, in a recent study, insertion of the type O FMDV epitope outside of the type Asia1 FMDV VP1 G-H loop triggered high levels of anti-type O FMDV IgG antibodies; however, it induced very low titres of neutralizing antibodies (Chai et al., 2013) . Based on their bioinformatic analyses, the authors proposed that the conformational abnormality of the exogenous epitope displayed on the capsid might be the main reason for the failure to generate a neutralizing epitope-specific response (Chai et al., 2013) . Previous work has demonstrated that structural stabilization of the foreign epitope may play an important role in the induction of a neutralizing antibody response (Eckhart et al., 1996) . Furthermore, we recently demonstrated that the 8E8 epitope is a conformationdependent linear epitope that can induce limited neutralizing antibodies by a single peptide component of VP1 without the conformational structural domain of VP2 (D. Yang, M. Liu, J. Wang & L. Yu, unpublished data). Thus, the failure to generate a neutralizing epitope-specific response in this study is probably due to the deficiency of the conformational structural domain of FMDV VP2. Future studies will explore the potential of other linear neutralizing epitopes displayed on the BEV-B capsid to induce neutralizing antibodies. In addition, because BEV enters its host via the enteric tract, it might stimulate mucosal immunity in the gastrointestinal tract; therefore, studies of the immunogenicity of the rBEVs in neonatal calves following oral vaccine administration should be conducted.
In conclusion, we generated two recombinant BEVs in which the type O FMDV neutralizing epitope 8E8 was inserted into the VP1 B-C or D-E loops. Our results demonstrated that the 8E8 epitope can be effectively displayed on the VP1 B-C and D-E loops of BEV-B and that positions 82/83 and 124/125 on the VP1 are probably the receptor-binding regions of BEV-B. Finally, the ability to generate recombinant BEVs displaying protective neutralizing epitopes is also an attractive choice for the study of virus-host interactions and may provide insights into the ecology of BEV by using foreign epitopes as a molecular marker.
METHODS
Cell lines, viruses and mAbs. BHK-21, IBRS-2, MDBK and Marc145 cells were grown in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10 % FBS, 100 U penicillin ml 21 and 100 mg streptomycin ml 21 at 37 uC with 5 % CO 2 . The BEV strain BHM26, which has been described in detail elsewhere (Li et al., 2012) , was propagated in BHK-21 cells. Virus titres were determined by microtitration using BHK-21 cells and expressed as TCID 50 , according to the Reed-Muench method (Reed & Muench, 1938) . mAb 8E8 was prepared by L. Zhao and co-workers (Yang et al., 2011) , and this antibody neutralized the FMDV O/YS/CHA/05 strain in 50 % of the wells at a 1 : 8192 dilution.
RNA extraction, reverse transcription and PCR. Total RNA was extracted from BEV-infected BHK-21 cells using Trizol reagent (Invitrogen). The extracted RNA was reverse transcribed using oligo(dT) primers and PrimeScript reverse transcriptase (TaKaRa)
according to the manufacturer's instructions, to produce cDNA. The resulting first-strand cDNA was used as template for subsequent PCR amplification of genome fragments, as described previously (Li et al., 2012) .
Construction of infectious cDNA clones of BEV/rBEVs. Primers (Tables S1 and S2) were designed based on the published sequence of BEV-B strain BHM26 (GenBank accession no. HQ917060; Li et al., 2012) to amplify specific fragments of the BHM26 genome. The primer pairs A1/A2, B1/B2 and C1/C2 (Table S1 ) were used to amplify cDNA fragments encompassing nt 1-2672, 2470-5293 and 5168-7411, respectively , which were designated A, B and C, and sequentially containing the NdeI, SalI, XhoI and BglII restriction enzyme sites (Fig.  1a) . Primer A1 contained a T7 promoter sequence, which was used to introduce the T7 promoter upstream of the full-length cDNA for efficient in vitro transcription. A PvuII restriction enzyme site was eliminated in the VP1 region by a silent mutation (nt 4074, CAT) to distinguish the rescued virus from the parental virus using the primer pair M1/M2 (Table S1 ). To prepare a full-length cDNA clone of the BHM26 strain, three fragments of A, B and C covering the complete genome of BEV-B BHM26 were cloned sequentially into the pOK12 vector (Vieira & Messing, 1991) backbone, and the obtained construct was designated pOKT7-BHM26 (Fig. 1a ).
Subsequently, using the BEV-B infectious clone pOKT7-BHM26 as a backbone, a series of recombinant plasmids containing the 8E8 epitope-encoded DNA were constructed. Briefly, plasmid pOKT7-BHM26 served as DNA template for overlapping PCR. To construct the recombinant plasmid pBEV-A, two primer pairs, 1517U23/ 2712L58 and 2734U57/3986L23 (Table S2) , were used for PCR amplification to obtain 1253 and 1275 bp fragments, and subsequent amplification was performed using the flanking primers 1517U23 and 3986L23 (Table S2 ). The amplified 8E8 epitope-encoded fragment was digested by EcoRI and NgoMIV and subsequently inserted into the pOKT7-BHM26 vector, which was simultaneously digested by EcoRI and NgoMIV to yield pBEV-A. The other recombinant plasmids (pBEV-A1, A2, O, DE, B, C1, C, D, Y, Y1, P, F, G, W, W1, K, S, S1, S2, S3 and S4) were constructed in the same manner according to the information in Table S2 . All of the recombinant plasmids were sequenced to confirm the desired insertion.
In vitro transcription, transfection and virus rescue. The pOKT7-BHM26 plasmid or recombinant plasmids were digested with BglII, purified and used as templates for in vitro transcription. In vitro transcription was performed using a RiboMAX Large Scale RNA Production Systems-T7 kit (Promega) according to the manufacturer's instructions. The transcribed RNA was transfected into BHK-21 cells using Effectene Transfection Reagent (Qiagen) according to the manufacturer's instructions. When the cells exhibited 50-80 % CPE after transfection, the cell cultures were frozen and thawed three times to harvest the cell lysates. The specificity of the parental BEV or rBEVs was identified by IFA as described below. Virus neutralization test. A micro-neutralization assay was performed essentially according to the OIE manual (http://www.oie.int/ fileadmin/Home/eng/Health_standards/tahm/2.01.05_FMD.pdf). Briefly, twofold serial dilutions of heat-inactivated sera or mAb 8E8 were incubated with 100 TCID 50 FMDV O/YS/CHA/05, parental BEV or rBEVs for 1 h at 37 uC in a 96-well microplate. Approximately 10 4 BHK-21 cells in 100 ml medium were added per well, incubated for 5 days and then examined for CPE. The assay was performed independently three times. The neutralizing titre was calculated using the Kärber method (Kärber, 1931) .
Inoculation of BALB/c mice. A total of 15 6-week-old specificpathogen-free BALB/c mice were randomly divided into three groups of five mice each. The mice in groups A, B and C were inoculated intramuscularly with two doses of rBEV-A1, rBEV-DE or the parental virus BHM26, respectively, at a titre of 2610 7 TCID 50 for each mouse. Serum samples were collected and tested for anti-type O FMDV antibodies and anti-BEV-B antibodies. The mice that were inoculated were bled at 2-week intervals until 14 weeks p.i. The inoculation and blood collection were performed under ether anaesthesia. At the end of the experiment, the mice were euthanized.
Indirect ELISA. Each well of a 96-well plate was coated with 100 ng purified FMDV O/YS/CHA/05 or BEV BHM26 antigen (100 ml per well in 0.1 M NaHCO 3 , pH 8.6) overnight at 4 uC. The coated wells were blocked with 5 % skimmed milk in PBS. The sera of BALB/c mice were added to each well at a dilution of 1 : 100 in PBST (16PBS with 0.05 % Tween 20), and the plates were incubated at 37 uC for 1 h. After this incubation, HRP-conjugated goat anti-mouse IgG (Sigma) was added at a dilution of 1 : 10 000. The reaction was quantified by detecting the absorbance value at 450 nm (A 450 ) using 3,39,5,59-tetramethylbenzidine as substrate.
